BioCryst Pharmaceuticals, Inc.: BioCryst Announces Preliminary Full Year 2024 ORLADEYO (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
ORLADEYO net revenue expected to be between $515-$535 million in 2025- -Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025- -Company achieved operating profit in 2024 ...
HMPV virus protection: 5 prevention strategies for offices to control the HMPV virus spread
Human Metapneumovirus (HMPV) poses a significant threat, especially to vulnerable groups, with symptoms akin to the common ...
CorMedix, Inc.: CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update
Q4 2024 Unaudited Net Revenue of Approximately $31mm ? ? FY 2024 Unaudited Net Revenue of Approximately $43mm ? ? Expects Q4 Adjusted EBITDA to Exceed $12mm ? BERKELEY HEIGHTS, N.J., Jan. 07, 2025 ...
As prevention strategy for sexually transmitted infections rolls out, experts highlight both promise and knowledge gaps
As health care services begin offering doxycycline to prevent bacterial sexually transmitted infections (STIs), real-world ...